Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
ABSI vs TWST: Weighing Momentum and Catalysts in AI-Driven Biotech

ABSI vs TWST: Weighing Momentum and Catalysts in AI-Driven Biotech

Key Takeaways

  • ABSI and TWST both operate at the intersection of biotechnology and artificial intelligence (AI), but they serve different ends of the market: Absci designs therapeutic antibodies with generative AI, while Twist supplies synthetic DNA and sequencing tools.
  • Twist (TWST) has a far larger and more stable revenue base, while Absci (ABSI) carries stronger recent share-price momentum and a nearer-term clinical catalyst.
  • Tickeron AI Verdict: ABSI — based on observable momentum, trend consistency, and an upcoming proof-of-concept catalyst, the AI currently favors ABSI over TWST.
  • Both companies remain unprofitable, making sentiment and milestone-driven catalysts key drivers of their relative performance.
  • For deeper coverage, explore ABSI Major News, ABSI Today's Price Move, TWST Major News, and TWST Today's Price Move.
  • To see which strategies are currently favored across the market, explore Trending AI Robots.

Introduction

Investors comparing ABSI (Absci Corporation) and TWST (Twist Bioscience Corporation) are effectively weighing two distinct ways to gain exposure to AI-driven biotechnology. Absci is a clinical-stage drug developer using generative AI to design therapeutic antibodies, while Twist is a synthetic biology tools provider whose products underpin drug discovery and genomics. Although both sit in the broader AI-biotech theme, their risk profiles, revenue models, and catalysts differ meaningfully. This stock comparison is most relevant to growth-oriented traders and investors evaluating relative performance, market positioning, and momentum between two high-beta, pre-profit names. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ABSI Overview and Recent Performance

Absci Corporation (ABSI) is a clinical-stage biopharmaceutical company that combines generative AI models with a synthetic biology data engine to design novel antibody therapeutics. Its lead program, ABS-201, is being studied for androgenetic alopecia (a common form of hair loss) and endometriosis, while additional internal programs target inflammatory bowel disease (IBD) and oncology. In recent weeks, the company has reported continued advancement of its Phase 1/2a HEADLINE trial, with interim proof-of-concept data anticipated in late 2026 and full data expected in early 2027. Share-price momentum has been notable over the trailing year, with the stock up sharply from its 52-week lows, though it remains volatile and well below earlier highs. Institutional interest has strengthened, and analyst coverage skews toward Buy ratings with consensus targets above recent trading levels. Sentiment has been driven primarily by the approaching clinical readout and the company's positioning as a pure-play on AI-designed drugs, offset by minimal current revenue and ongoing cash burn.

TWST Overview and Recent Performance

Twist Bioscience Corporation (TWST) is a synthetic biology company that manufactures synthetic DNA and provides next-generation sequencing (NGS) tools used across drug discovery, diagnostics, and agriculture. Its SynBio segment has delivered consistent double-digit growth, while its NGS business has benefited from diagnostic customers and population-genetics applications. In its most recently reported fiscal year, Twist generated record revenue of roughly $376 million, representing about 20% growth, and improved gross margin to approximately 50%. The company has also flagged growing demand from AI-enabled drug discovery projects. However, it remains unprofitable and has noted a temporary slowdown in NGS revenue tied to a customer transition. Recent market activity has reflected a balance between improving fundamentals and lingering questions about the timeline to sustained profitability, with the stock trading in a broad range over recent months. From what I see, checking the latest filings confirms these trends.

Trending AI Robots

Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers across varying styles, strategies, timeframes, and risk profiles. Because no single bot suits every market condition, Tickeron curates only the most relevant performers into its Trending AI Robots section. This page highlights bots that are currently aligned with prevailing market conditions, giving traders a focused view of strategies showing relative strength rather than an overwhelming catalog. Bots on the platform differ in trading frequency, asset coverage, and historical performance statistics, allowing users to evaluate options suited to their own objectives. For traders tracking names like ABSI and TWST, reviewing Trending AI Robots can offer a data-driven starting point for understanding which approaches are currently gaining traction.

Head-to-Head Comparison

The core contrast between these two companies lies in business model and stage. TWST is a revenue-generating tools and services business with a diversified customer base and a path toward operating leverage, but its growth is steadier and its margin improvement gradual. ABSI is an earlier-stage, catalyst-dependent developer with minimal revenue but a binary upside tied to clinical data. On momentum, ABSI has shown the stronger relative performance over recent months, supported by a defined near-term catalyst, while TWST has been comparatively range-bound. On risk, ABSI carries higher volatility and binary clinical risk, whereas TWST faces execution and profitability-timeline risk. Sector exposure also differs: Absci is concentrated in AI-driven therapeutics, while Twist is diversified across genomics, diagnostics, and agriculture. Neither stock currently offers profitability, so valuation rests heavily on future growth expectations rather than earnings.

Tickeron AI Verdict

Weighing observable factors such as trend consistency, momentum, and catalyst proximity, Tickeron's AI would currently lean toward ABSI over TWST. Absci's stronger relative price momentum, rising institutional positioning, and an imminent clinical proof-of-concept readout provide a clearer near-term catalyst profile. Twist offers a more stable revenue foundation and improving margins, but its momentum has been less pronounced and its growth trajectory more gradual. This assessment is probabilistic rather than definitive: it reflects current trend and catalyst dynamics, which can shift quickly in high-volatility biotech names. I’m watching this closely as the data evolves.

Exploring AI Tools for Deeper Analysis

In my view, one resource that adds real value when comparing names like these is Tickeron’s AI Screener. It lets me quickly scan for relative strength, momentum signals, and industry peers without sifting through endless data. I find it particularly helpful for confirming whether a catalyst story holds up against broader sector trends before making allocation decisions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TWST, ABSI

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


TWST in downward trend: price dove below 50-day moving average on October 30, 2026

TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 62 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 63 cases where TWST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

Following a +10.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.596). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of proprietary semiconductor-based synthetic DNA manufacturing process

Industry Biotechnology

Industry
Biotechnology
Address
681 Gateway Boulevard
Phone
+1 800 719-0671
Employees
979
Web
https://www.twistbioscience.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.